These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

454 related items for PubMed ID: 11390647

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Glial cell line-derived neurotrophic factor differentially stimulates ret mutants associated with the multiple endocrine neoplasia type 2 syndromes and Hirschsprung's disease.
    Carlomagno F, Melillo RM, Visconti R, Salvatore G, De Vita G, Lupoli G, Yu Y, Jing S, Vecchio G, Fusco A, Santoro M.
    Endocrinology; 1998 Aug; 139(8):3613-9. PubMed ID: 9681515
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Signaling complexes and protein-protein interactions involved in the activation of the Ras and phosphatidylinositol 3-kinase pathways by the c-Ret receptor tyrosine kinase.
    Besset V, Scott RP, Ibáñez CF.
    J Biol Chem; 2000 Dec 15; 275(50):39159-66. PubMed ID: 10995764
    [Abstract] [Full Text] [Related]

  • 5. Ret oncogene signal transduction via a IRS-2/PI 3-kinase/PKB and a SHC/Grb-2 dependent pathway: possible implication for transforming activity in NIH3T3 cells.
    Hennige AM, Lammers R, Arlt D, Höppner W, Strack V, Niederfellner G, Seif FJ, Häring HU, Kellerer M.
    Mol Cell Endocrinol; 2000 Sep 25; 167(1-2):69-76. PubMed ID: 11000521
    [Abstract] [Full Text] [Related]

  • 6. Increased in vivo phosphorylation of ret tyrosine 1062 is a potential pathogenetic mechanism of multiple endocrine neoplasia type 2B.
    Salvatore D, Melillo RM, Monaco C, Visconti R, Fenzi G, Vecchio G, Fusco A, Santoro M.
    Cancer Res; 2001 Feb 15; 61(4):1426-31. PubMed ID: 11245446
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Two distinct mutations of the RET receptor causing Hirschsprung's disease impair the binding of signalling effectors to a multifunctional docking site.
    Geneste O, Bidaud C, De Vita G, Hofstra RM, Tartare-Deckert S, Buys CH, Lenoir GM, Santoro M, Billaud M.
    Hum Mol Genet; 1999 Oct 15; 8(11):1989-99. PubMed ID: 10484767
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Various mechanisms cause RET-mediated signaling defects in Hirschsprung's disease.
    Pelet A, Geneste O, Edery P, Pasini A, Chappuis S, Atti T, Munnich A, Lenoir G, Lyonnet S, Billaud M.
    J Clin Invest; 1998 Mar 15; 101(6):1415-23. PubMed ID: 9502784
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. The Shb adaptor protein binds to tyrosine 766 in the FGFR-1 and regulates the Ras/MEK/MAPK pathway via FRS2 phosphorylation in endothelial cells.
    Cross MJ, Lu L, Magnusson P, Nyqvist D, Holmqvist K, Welsh M, Claesson-Welsh L.
    Mol Biol Cell; 2002 Aug 15; 13(8):2881-93. PubMed ID: 12181353
    [Abstract] [Full Text] [Related]

  • 13. Tissue-specific carcinogenesis in transgenic mice expressing the RET proto-oncogene with a multiple endocrine neoplasia type 2A mutation.
    Kawai K, Iwashita T, Murakami H, Hiraiwa N, Yoshiki A, Kusakabe M, Ono K, Iida K, Nakayama A, Takahashi M.
    Cancer Res; 2000 Sep 15; 60(18):5254-60. PubMed ID: 11016655
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Characterization of Ret-Shc-Grb2 complex induced by GDNF, MEN 2A, and MEN 2B mutations.
    Ohiwa M, Murakami H, Iwashita T, Asai N, Iwata Y, Imai T, Funahashi H, Takagi H, Takahashi M.
    Biochem Biophys Res Commun; 1997 Aug 28; 237(3):747-51. PubMed ID: 9299438
    [Abstract] [Full Text] [Related]

  • 16. Signalling of the Ret receptor tyrosine kinase through the c-Jun NH2-terminal protein kinases (JNKS): evidence for a divergence of the ERKs and JNKs pathways induced by Ret.
    Chiariello M, Visconti R, Carlomagno F, Melillo RM, Bucci C, de Franciscis V, Fox GM, Jing S, Coso OA, Gutkind JS, Fusco A, Santoro M.
    Oncogene; 1998 May 14; 16(19):2435-45. PubMed ID: 9627110
    [Abstract] [Full Text] [Related]

  • 17. Enhanced phosphatidylinositol 3-kinase activity and high phosphorylation state of its downstream signalling molecules mediated by ret with the MEN 2B mutation.
    Murakami H, Iwashita T, Asai N, Shimono Y, Iwata Y, Kawai K, Takahashi M.
    Biochem Biophys Res Commun; 1999 Aug 19; 262(1):68-75. PubMed ID: 10448070
    [Abstract] [Full Text] [Related]

  • 18. A mutation at tyrosine 1062 in MEN2A-Ret and MEN2B-Ret impairs their transforming activity and association with shc adaptor proteins.
    Asai N, Murakami H, Iwashita T, Takahashi M.
    J Biol Chem; 1996 Jul 26; 271(30):17644-9. PubMed ID: 8663426
    [Abstract] [Full Text] [Related]

  • 19. The Glu632-Leu633 deletion in cysteine rich domain of Ret induces constitutive dimerization and alters the processing of the receptor protein.
    Bongarzone I, Vigano E, Alberti L, Mondellini P, Uggeri M, Pasini B, Borrello MG, Pierotti MA.
    Oncogene; 1999 Aug 26; 18(34):4833-8. PubMed ID: 10490816
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.